|Articles|May 1, 2001
Melanoma risk guides management of patients with melanocytic nevi
Washington - Management of patients with melanocytic nevi maybe improved in the future by advances that allow identification of congenitalnevi that are obligate precursors for malignant melanoma and true risk markersfor melanoma in individuals with dysplastic nevi, Darrell S. Rigel, M.D.,said at the annual meeting of the American Academy of Dermatology.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
2
Highlighting Major Breakthroughs for Atopic Dermatitis and Psoriasis in 2025
3
Expert Panel Unanimously Backs DecisionDx-Melanoma for Guiding Personalized Cancer Care
4
Considering Biologics and Shared Decision-Making in Moderate to Severe Plaque Psoriasis: Part 2
5













